Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Overcoming the hurdles to achieving glycemic control.

Kenneth M Shaw1

  • 1Academic Department of Diabetes and Endocrinology, Queen Alexandra Hospital Cosham, Portsmouth, PO6 3LY, UK. ken.shaw@porthosp.nhs.uk

Metabolism: Clinical and Experimental
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of atmospheric pressure change during flight on insulin pump delivery and glycaemic control of pilots with insulin-treated diabetes: an in vitro simulation and a retrospective observational real-world study.

Diabetologia·2024
Same author

Continuous Glucose Monitoring by Insulin-Treated Pilots Flying Commercial Aircraft Within the ARA.MED.330 Diabetes Protocol: A Preliminary Feasibility Study.

Diabetes technology & therapeutics·2023
Same author

Blood glucose monitoring by insulin-treated pilots of commercial and private aircraft: An analysis of out-of-range values.

Diabetes, obesity & metabolism·2021
Same author

An Evaluation of the Safety of Pilots With Insulin-Treated Diabetes in Europe Flying Commercial and Noncommercial Aircraft.

Diabetes care·2020
Same author

Nitrate tolerance and the links with endothelial dysfunction and oxidative stress.

British journal of clinical pharmacology·2003
Same journal

Pathophysiology-based subtypes of individuals at high-risk of type 2 diabetes: multi-omics profiles and lifestyle differences across subtypes.

Metabolism: clinical and experimental·2026
Same journal

A thermosensitive TET-Parkin epigenetic axis couples mitochondrial quality control to adaptive thermogenesis in adipose tissue.

Metabolism: clinical and experimental·2026
Same journal

Raffinose targets the NQO1/NF-κB axis to attenuate DON-driven microglial activation and neuroinflammation via metabolic reprogramming.

Metabolism: clinical and experimental·2026
Same journal

Endothelial NPR-C promotes insulin resistance via Caveolin-1-mediated insulin transcytosis.

Metabolism: clinical and experimental·2026
Same journal

Macrophage-enriched GPR91 aggravates acute liver injury by inhibiting efferocytosis via the AC/cAMP/PPARγ pathway.

Metabolism: clinical and experimental·2026
Same journal

Corrigendum to "TMEM41B contributes to atherosclerosis by promoting lipid synthesis in vascular smooth muscle cells via fatty acid synthase stabilization" [Metabolism 175 (2026) 156456].

Metabolism: clinical and experimental·2026
See all related articles

Optimizing glycemic control in type 2 diabetes mellitus is challenging. Once-daily gliclazide modified release improves medication adherence and HbA1c levels, with a reduced risk of hypoglycemia.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) management is complex, with factors impacting glycemic control.
  • Over time, patients often experience reduced medication responsiveness and difficulty achieving target blood glucose levels.
  • Modifiable factors, including lifestyle and confounding conditions, significantly influence diabetes outcomes.

Purpose of the Study:

  • To evaluate the efficacy and adherence benefits of gliclazide modified release in T2DM patients.
  • To compare glycemic control and hypoglycemia risk with gliclazide modified release versus glimepiride.

Main Methods:

  • A study comparing gliclazide modified release with glimepiride in T2DM patients.
  • Assessment of medication adherence and glycemic control (HbA1c levels).

Related Experiment Videos

  • Evaluation of hypoglycemia incidence as a key safety outcome.

    • Main Results:

    • Gliclazide modified release demonstrated improved medication adherence compared to standard regimens.
    • Patients on gliclazide modified release achieved better glycemic control, indicated by lower HbA1c levels.
    • The study showed a reduced risk of hypoglycemia with gliclazide modified release.

    Conclusions:

    • Once-daily gliclazide modified release enhances patient adherence and improves glycemic outcomes in T2DM.
    • Gliclazide modified release offers a safer alternative with a lower risk of hypoglycemia.
    • Simplifying treatment regimens, like with once-daily formulations, is crucial for effective T2DM management.